On Jul. 26, 2021, researchers at the University of Oxford launched a Phase 1 trial to test a new vaccine against plague.

Based on the ChAdOx1 adenovirus viral vector platform also used in the successful Oxford coronavirus vaccine, forty healthy adults aged 18 to 55 will receive this new vaccine in order to assess side effects and determine how well it induces protective antibody and T cell responses.